An Investigator/Subject Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of RO7034067 in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Risdiplam (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 09 Nov 2017 Status changed from recruiting to completed.
- 02 Oct 2017 Planned End Date changed from 16 Sep 2017 to 6 Oct 2017.
- 02 Oct 2017 Planned primary completion date changed from 16 Sep 2017 to 6 Oct 2017.